Oragenics Announces New Trading Symbol “OGEN” and Trading of Shares on Both the OTCQB and OTCBB
TAMPA, Fla.-- Oragenics, Inc. (OTCQB: OGEN) (OTCBB: OGEN) (www.oragenics.com) today announced that its new trading symbol on the OTCBB is “OGEN”. The Company’s shares are also trading on the OTCQB, an inter-dealer quotation system for publicly traded companies that are current in their SEC required filings, and its OTCQB trading symbol has also changed to “OGEN”.
“We believe the symbol change to “OGEN” better aligns our stock symbol with our brand name and while our shares trade on the OTCBB, the quotation of our shares on OTCQB remains a positive development because it provides access to the larger number of market makers and better trading platform that we believe the OTCQB provides,” said Dr. John Bonfiglio, the Company’s Chief Executive Officer. The OTCQB is owned by a private company, OTC Market Groups, Inc., which distinguishes its trading platform from the OTCBB on the basis of being more efficient by being an electronic trading platform rather than telephonic. Shareholders and potential investors can now obtain detailed trading information regarding the Company, including real-time bid and ask quotes, at http://www.otcmarkets.com/stock/OGEN/quote.
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in probiotics for oral health for humans and pets and in novel antibiotics against infectious disease. Oragenics, Inc. develops, markets and sells proprietary probiotics specifically designed to enhance oral health for humans and pets, under the brand names Evora and ProBiora in over 13 countries worldwide. Oragenics, Inc. has established an exclusive worldwide channel collaboration for lantibiotics, a novel class of broad spectrum antibiotics, with Intrexon Corporation, a synthetic biology company.
About OTC Markets Group Inc.
OTC Markets Group Inc. (OTCQX:OTCM) operates the world's largest Open, Transparent and Connected financial marketplace platform. Our OTC Link(R) ATS directly links a diverse network of broker-dealers that provide liquidity and execution services in almost 10,000 equity and debt securities. We organize these securities into marketplaces to inform investors of opportunities and risks - OTCQX(R) - The Intelligent Marketplace for the Best OTC Companies; OTCQB(R) - The Venture Marketplace; and OTC Pink(R) - The Open Marketplace. Our information and data-driven platform enables trading through any broker at the best possible price and empowers companies to improve the quality and availability of information for their investors. To learn more about how we create smarter financial marketplaces, visit www.otcmarkets.com.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
For more information regarding Oragenics, contact:
Chief Financial Officer
3000 Bayport Drive, Suite 685
Tampa, Fl 33607
Tel: 813-286-7900 x246
880 Third Avenue, 6th Floor
New York NY 10022
Tel: 1-800-625-2236 x7770
Michael Sullivan, 813-286-7900 x246
Chief Financial Officer
Robert Giordano, 1-800-625-2236 x7770
Source: Oragenics, Inc.
Released September 25, 2012